School of Medicine
Showing 1-10 of 460 Results
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly Interests Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.
Associate Professor of Pediatrics (Stem Cell Transplantation) at the Lucile Salter Packard Children's Hospital
Current Research and Scholarly Interests Hematopoietic Stem cell biology-created a SCID mouse model to study engraftment of cord blood derived hematopoietic cells and use of this model to develop gene transfer technology for Fanconi anemia.
Clinical research interests are to develop new protocols to reduce graft vs host disease,treatment of viral infections post transplant and use of manipulated HSC graft in patients who receive mismatched donor transplants.
Ash A. Alizadeh, MD/PhD
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly Interests My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.
Russ B. Altman
Kenneth Fong Professor and Professor of Bioengineering, of Genetics, of Medicine (General Medical Discipline), of Biomedical Data Science and, by courtesy, of Computer Science
Current Research and Scholarly Interests I refer you to my web page for detailed list of interests, projects and publications. In addition to pressing the link here, you can search "Russ Altman" on http://www.google.com/
Justin P. Annes M.D., Ph.D.
Assistant Professor of Medicine (Endocrinology)
Current Research and Scholarly Interests The ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders
The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.
(1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.
(2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.
HEREDIATY PARAGAGLIOMA SYNDROME
The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.
As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.
Sally Arai, MD
Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Current Research and Scholarly Interests Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.
Postdoctoral Research Fellow, Stanford Cancer Center
Bio Until now, most medical treatments have been designed for the “average patient.” As a result of this “one-size-fits-all” approach, treatments can be very successful for some patients but not for others. Precision Medicine, on the other hand, is an innovative approach that takes into account individual differences in people’s genes, environments, and lifestyles. The interaction between genetic, environmental and lifestyle factors is called epigenetics.
My research investigates the role of epigenetic changes in obesity and weight-loss to design precision-medicine solutions that are tailored to people’s unique characteristics. To this end I am studying how obesity and weight loss modify our epigenetic landscape, and how these changes interact with genetic and lifestyle factors to predict disease status and reversal for the design of personalized medicine strategies. My ultimate goal is to change the very nature of health care—true patient-centered care based upon prediction and prevention rather than relying exclusively on diagnosis and treatment.
For this project I have been awarded a Marie-Curie Fellowship, Europe’s most competitive research grant, scoring #1 among the applicants in the entire Life Sciences panel. Previously, I received a Hertha Firnberg award from the Austrian Science Funds, and became project leader at the Vienna-Biocenter in Austria. I have also received science communication awards from Europe PubMed Central and FameLab International. I have research experience from the University of Oxford, University Federico II of Naples, University of Vienna, University of Southern California, and Stanford University. I have published research papers in top-ranked peer reviewed journals such as Cell, Genes and Development, the EMBO Journal and Nucleic Acid Research.
Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Current Research and Scholarly Interests Telomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.
Ann M. Arvin
Vice Provost and Dean of Research, Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology
Current Research and Scholarly Interests Our laboratory investigates the pathogenesis of varicella zoster virus (VZV) infection, focusing on the functional roles of particular viral gene products in pathogenesis and virus-cell interactions in differentiated human cells in humans and in Scid-hu mouse models of VZV cell tropisms in vivo, and the immunobiology of VZV infections.